Open Access Full Text Article

CORRIGENDUM

Total Lymphocyte Count, Neutrophil-Lymphocyte Ratio, and Platelet-Lymphocyte Ratio as Prognostic Factors in Advanced Non-Small Cell Lung Cancer with Chemoradiotherapy [Corrigenudm]

Song X, Chen D, Yuan M, Wang H, Wang Z. Cancer Manag. 2018;10:6677–6683

On page 6677, Abstract, Results subheading, the median baseline PLR should be 136.1.

On page 6680, Results section, 2^{nd} paragraph, the median baseline PLR should be 136.1.

On page 6680, the red curve should be PLR \geq 136.1 and the blue cure should be PLR <136.1. The COX analysis was not correct in the previous publication and it has been revised and shown below in the new Tables 1 and table 2. The correct Figure 3 is shown below.



Figure 3 Kaplan–Meier plots of overall survival among patients who receivedchemoradiotherapy for advanced NSCLC stratified by baseline PLR. Abbreviations: NSCLC, non–small cell lung cancer; PLR, platelet-tolymphocyteratio. On page 6680, Table 2, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 2 is shown below.

Over all Sul vival									
Characteristics	HR	95% CI	P Value						
Age ≥65	0.778	0.609–0.994	0.045						
Male	0.935	0.733-1.193	0.588						
KPS score ≥70	1.100	0.762-1.588	0.611						
TNM stage IIIB	1.024	0.763-1.375	0.874						
Current smoker	0.918	0.748-1.126	0.412						
Receipt of induction	1.127	0.881-1.443	0.342						
chemotherapy									
Receipt of concurrent	0.868	0.660-1.143	0.314						
chemotherapy									
Pretreatment TLC $\geq 2.4 \times 10^3/\mu L$	0.594	0.464-0.759	<0.001						
Pretreatment NLR ≥3.4	2.280	1.776–2.927	<0.001						

 Table 2 Univariate analysis of factors potentially associated with overall survival

Abbreviations: HR, hazard ratio; Cl, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to -lymphocyte ratio.

Pretreatment PLR ≥136.1

1.745

1.364-2.232

<0.001

On page 6681, Table 3, the COX analysis was not correct in the previous publication and it has been revised. The correct Table 3 is shown below.



1135

© 121 Song et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the frems. Non-commercial uses of the work are permitted without any further permission for Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial uses of this work, please see paragraphs 4.2 and 5 of our Terms (http://www.dovepress.com/terms.php).

	Model I (TLC Included)			Model 2 (NLR Included)			Model 3 (PLR Included)		
	HR	95% CI	P Value	HR	95% CI	P Value	HR	95% CI	P Value
Characteristics									
Age ≥65	0.902	0.697-1.167	0.431	0.858	0.67-1.099	0.226	0.825	0.645-1.054	0.124
Pretreatment TLC ≥2.4 × 10 ³ /µL	0.613	0.474-0.794	<0.001						
Pretreatment NLR ≥3.4				2.231	1.734-2.87	<0.001			
Pretreatment PLR ≥136.1							1.71	1.333-2.185	<0.001

Table 3 Multivariate analysis of factors potentially associated with overall survival Model I (TLC included)

Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; TNM, tumor-nodes-metastasis; TLC, total lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

The authors have advised errors were caused by carelessness and mis-operation in statistics. The authors apologize for this error and advise it does not affect the results of the paper.

Cancer Management and Research

Dovepress

Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal